Impact of Reducing Dietary Intake of Red and Processed Meat Intake on Fasting Lipemia in Healthy Participants (ELM)
調査の概要
詳細な説明
In UK adults, meat provides approximately 40% of the average daily protein intake and makes a significant contribution to intake of thiamin, niacin, vitamin B12, iron, zinc, potassium, and phosphorus. However, excessive consumption, particularly of red and processed meat, is associated with increased risk of developing a range of chronic diseases, including cardiovascular disease (CVD), obesity, type 2 diabetes and some cancers. Meat production significantly contributes to the production of greenhouse gasses (GHG) and hence global warming. Given the predicted global increase in the human population, coupled with the rise in demand for meat within emerging economies, it has been suggested that concerted efforts should be made to alter dietary patterns and reduce meat intake. Moreover, a number of reports have suggested that replacing meat with non-meat protein-rich products has health benefits. Such products tend to be inherently lower in total and saturated fat and, higher in fibre and as such, could also be cardioprotective.
The aim of this trial will be to investigate whether, with appropriate non/reduced-meat alternatives and motivational support, free living subjects can significantly reduce their meat intake and whether such dietary changes positively impact on a range of cardiovascular risk factors.
Trial design; A non-randomised, single group study design, with an initial control period will be used.
Participants; Forty healthy men and women will be recruited from the general population of Nottinghamshire, UK. All participants will attend the David Greenfield Human Physiology Unit (Queen's Medical Centre, Nottingham, UK) for an initial medical screening visit to confirm health status. In addition, blood pressure (BP) will be measured at the left upper arm (after lying semi-supine for 5min) using automated oscillometry, and body mass index (BMI) will be calculated from measured height and weight. If participants are suitable to take part with regards to their health questionnaire and BMI measures, a venous blood sample will then be taken to assess full blood count, urea, and electrolytes. Those taking lipid-lowering medication, or who report using nutritional strategies to lower their cholesterol, will be excluded. Participants will be accepted onto the trial if they report habitual consumption of 4-5 portions of red and/or processed meat per week (with 3-4 of these being consumed as main meals), they do not have food allergies related to soya or mycoprotein, and do not demonstrate any clinically significant abnormalities on screening.
Study Protocol; After recruitment, participants will be asked to record all food intake (including snacks and drinks) in a diet diary, for 4 days (3x week or work days, and 1x weekend or rest day) prior to assessment visit 1, for baseline assessment of macronutrient and energy intake. Individuals will be asked to complete further 4-day diet diaries in the week before assessment visits 2,3 and 4 (weeks 4, 10, and 16), to assess any changes in macronutrient or energy intake and meat consumption which may have occurred as a consequence of the intervention. Household measures will be used to estimate portion size, and diaries will be analysed using a food composition database. To calculate habitual diet composition, a mean daily intake will obtained from all 4 days of each recording period, and these data will be combined to produce group means.
Assessment visits will take place in the morning after the individual has fasted from midnight the night before. Initially, measurement of body mass will be made to the nearest 0.1kg using a Seca 882 Digital Scale, and waist and hip circumference will be assessed (with the participant standing) mid-way between the lowest rib and the iliac crest, and at the greater trochanters, respectively. Participants will then be asked to rest, semi-supine, on a couch for >5min before having their resting BP measured, and estimation of body composition made using bioelectrical impedance. A 5ml fasting blood sample will be taken for determination of serum insulin, total cholesterol, high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), triacyl glycerides (TAG) and whole blood glucose. In a subset of the cohort (n=26, 13 Male:13 Female), flow mediated dilatation (FMD) will also be measured on the laboratory visits when fasted, after resting semi-supine for 1 and 2 hours.
Intervention; After visit 1 (week 0) assessment, participants will be asked not to make any changes to their lifestyle and to continue their habitual diet until visit 2 (week 4) when a second assessment will be made ('control' period). The 12 week 'intervention' period will begin on the day after the second study visit. Participants will be given information regarding how meat intake can safely be reduced in their diet, including a recipe book containing ideas for meals using meat analogues and other protein sources. A range of frozen meat-free (soya or mycoprotein 'mince', mycoprotein sausages, meatballs and 'steak strips') and reduced meat products (pork sausages, beef meatballs, beef mince and beef burgers made with 50% meat and 50% soya or mycoprotein) are available for the participants to use to aid this reduction in red meat intake. In addition, a range of dried beans (red kidney, haricot, black turtle), pulses (chick peas, green and red lentils) and grains (quinoa) will also be offered. Weekly telephone contact with the study participants will be maintained over the intervention period to improve compliance, to identify any problems and to arrange further food deliveries.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Notts
-
Nottingham、Notts、イギリス、NG72UH
- David Greenfield Human Physiology Unit
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
BMI 18 - 28 kg/m2 Healthy Females should be premenopausal Good spoken and written English Consume 4-5 portions of red and/or processed meat per week consumption of greater than 70g per day
Exclusion Criteria:
Smoking Chronic diseases Hypertension Pregnancy / Breast feeding Chronic medication use (excluding oral contraceptives) Participation in any other research study three months prior to the screening or during study duration Clinically significant findings at screening
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Control
Participants to continue on their habitual diet for 4 weeks
|
|
|
実験的:Meat Reduction
Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
|
Advice, Motivational material and food products provided to participants
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting Serum total cholesterol concentration
時間枠:Week 0, 4,10 and 16
|
Fasting Serum total cholesterol concentration
|
Week 0, 4,10 and 16
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting Serum LDL cholesterol concentration
時間枠:Week 0, 4,10 and 16
|
Fasting Serum LDL cholesterol concentration
|
Week 0, 4,10 and 16
|
|
Fasting Serum HDL cholesterol concentration
時間枠:Week 0, 4,10 and 16
|
Fasting Serum HDL cholesterol concentration
|
Week 0, 4,10 and 16
|
|
Fasting whole blood glucose concentration
時間枠:Week 0, 4,10 and 16
|
Fasting whole blood glucose concentration
|
Week 0, 4,10 and 16
|
|
Fasting Serum Insulin concentration
時間枠:Week 0, 4,10 and 16
|
Fasting Serum Insulin concentration
|
Week 0, 4,10 and 16
|
|
Resting, supine blood pressure
時間枠:Week 0, 4,10 and 16
|
Resting, supine blood pressure (systolic and diastolic)
|
Week 0, 4,10 and 16
|
|
Body mass index calculated from measured height and weight (BMI)
時間枠:Week 0, 4,10 and 16
|
Body mass index calculated from measured height and weight (BMI)
|
Week 0, 4,10 and 16
|
|
% body fat determined by Bio-electrical Impedance
時間枠:Week 0, 4,10 and 16
|
% body fat determined by Bio-electrical Impedance
|
Week 0, 4,10 and 16
|
|
Flow-mediated dilatation
時間枠:Week 0, 4 and 16
|
Flow mediated dilatation at the brachial artery, measured using ultrasound (in a subset of participants)
|
Week 0, 4 and 16
|
|
Quality of Life Questionnaire
時間枠:Week 0, 4,10 and 16
|
WHOQOL Questionnaire
|
Week 0, 4,10 and 16
|
|
Dietary macro-nutrient intake
時間枠:Week 0, 4,10 and 16
|
Macro-nutrient intake of the diet determined from diet diaries
|
Week 0, 4,10 and 16
|
|
Dietary energy intake
時間枠:Week 0, 4,10 and 16
|
Energy intake of the diet determined from diet diaries
|
Week 0, 4,10 and 16
|
|
Meat intake
時間枠:Week 0, 4,10 and 16
|
daily red and processed meat intake determined from diet diaries
|
Week 0, 4,10 and 16
|
|
Full blood count
時間枠:Week 0,10 and 16
|
blood cell count, including haemoglobin
|
Week 0,10 and 16
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Andrew Salter, PhD、University of Nottingham
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- TS/L005891/1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。